Galiximab is a chimeric monoclonal antibody directed against CD80. Galiximab binds to CD80 and induces cross-linking of CD80 molecules and cell-death via ADCC. Galiximab has been investigated for the treatment of relapsed Hodgkin lymphoma.
BOC Sciences specializes in small molecule synthesis, biosynthesis, purification, and characterization. It provides a wide range of research chemicals and biochemicals, including inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP Products, impurities and metabolites, APIs, natural compounds, ADCs, stem cell molecules and chiral compounds.